ArticleClinical nuclear medicine2017
Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI.
Article in Clinical nuclear medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Positron Emission Tomography/Computed Tomography in Bladder Cancer: The Role of [Medicina (Kaunas, Lithuania) · 2026Review
- Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.Cancers · 2026Review
- Diagnostic efficacy of [Discover oncology · 2025Article
- Performance ofiScience · 2024Article
- PET Imaging in Bladder Cancer: An Update and Future Direction.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.Cancers · 2022Review
- Clinical value ofUrologic oncology · 2021Article
- The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment.Diagnostics (Basel, Switzerland) · 2021Review
- Imaging and Management of Bladder Cancer.Cancers · 2021Review
- Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer.Translational andrology and urology · 2020Review
- The Role of Imaging in Bladder Cancer Diagnosis and Staging.Diagnostics (Basel, Switzerland) · 2020Review
- The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.Frontiers in oncology · 2020Review
- [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo].Der Urologe. Ausg. A · 2019Review
- The influence of post-diuretic late phase imaging in visual and quantitative evaluation of urothelial tumors by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.Turkish journal of urology · 2019Article
- Evaluation of lymph node status in patients with urothelial carcinoma-still in search of the perfect imaging modality: a systematic review.Translational andrology and urology · 2018Review
- A glance at imaging bladder cancer.Clinical and translational imaging · 2018Article
- Advances in Imaging in Prostate and Bladder Cancer.Current urology reports · 2017Review
- Image-Guided Transurethral Resection of Bladder Tumors - Current Practice and Future Outlooks.Bladder cancer (Amsterdam, Netherlands) · 2017Review
- Synergy of PET and MR imaging in the local and regional staging of bladder cancer.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
purposeThe aim of this study was to conduct a prospective pilot study comparing the diagnostic performance of MRI alone and F-FDG simultaneous PET/MRI using a diuresis protocol in bladder cancer patients.
methodsTwenty-two bladder cancer patients underwent F-FDG PET/MRI, using intravenous furosemide and oral hydration for bladder clearance. A radiologist scored probability of tumor in 3 locations (urinary bladder, pelvic lymph nodes, nonnodal pelvis) using 1- to 3-point scale (1 = negative, 2 = equivocal, 3 = definite tumor). A nuclear medicine physician reviewed fused PET/MRI images, after which scores were reassigned based on combined findings. Follow-up pathologic and imaging data served as reference. Performances of MRI alone and PET/MRI were compared.
resultsOf these patients, 82%, 38%, and 18% were positive for bladder, pelvic nodal, and nonnodal pelvic tumor, respectively. At a score of 3, PET/MRI exhibited greater accuracy for detection of bladder tumor (86% vs 77%), metastatic pelvic lymph nodes (95% vs 76%), and nonnodal pelvic malignancy (100% vs 91%). In the bladder, PET changed the level of suspicion in 36% of patients (50% increased suspicion, 50% decreased suspicion), with 75% of these changes deemed correct based on reference standard. For pelvic lymph nodes, PET changed suspicion in 52% (36% increase, 64% decrease), with 95% of changes deemed correct. For nonnodal pelvis, PET changed suspicion in 9% (100% increase), with 100% deemed correct.
conclusionsAdditional PET information helped to appropriately determine level of suspicion in multiple anatomic sites for otherwise equivocal findings on MRI alone. Although requiring larger studies, findings suggest a possible role for simultaneous PET/MRI to assist bladder cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.